Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aliskiren

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: Aliskiren. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2007-005401-22 Sponsor Protocol Number: 24092007 Start Date*: 2009-02-20
    Sponsor Name:University Medical Center Utrecht
    Full Title: Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease
    Medical condition: Hypertension and chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001562-42 Sponsor Protocol Number: CSPP100A2370 Start Date*: 2013-12-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, wi...
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SK (Completed) HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004579-39 Sponsor Protocol Number: CSPP100A2332 Start Date*: 2006-09-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with ...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006066-42 Sponsor Protocol Number: CSPA100A2303 Start Date*: 2008-10-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, eight-week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (300/5 mg and 300/10 mg) in comparison with...
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) IS (Completed) EE (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001061-17 Sponsor Protocol Number: CSPP100A2306 Start Date*: 2005-04-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide (HCTZ), followed by a 4 week ...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed) IS (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004015-38 Sponsor Protocol Number: CSPP100A2323 Start Date*: 2005-03-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000862-21 Sponsor Protocol Number: CSPP100A2353 Start Date*: 2008-06-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren...
    Medical condition: hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003905-26 Sponsor Protocol Number: CSPP100A2309 Start Date*: 2005-06-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week, double-blind, parallel group study to evaluate the efficacy and safety of the combination of aliskiren with HCTZ compared to irbesartan or amlodipine with HCTZ or HCTZ alone in hypertens...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004104-31 Sponsor Protocol Number: CSPP100F2301 Start Date*: 2009-03-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compar...
    Medical condition: Chronic heart failure (NYHA Class II - IV)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SK (Completed) NL (Completed) FI (Completed) SE (Completed) DK (Completed) LT (Completed) BE (Completed) PT (Completed) IT (Completed) IE (Completed) ES (Completed) CZ (Completed) PL (Completed) FR (Completed) LV (Completed) GB (Completed) EE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004014-16 Sponsor Protocol Number: CSPP100A2313 Start Date*: 2005-04-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in patients wi...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002252-33 Sponsor Protocol Number: CSPP100A2304 Start Date*: 2005-01-28
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in p...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003199-23 Sponsor Protocol Number: CSAH100A2302 Start Date*: 2008-09-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to seve...
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) LT (Completed) LV (Completed) SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002635-27 Sponsor Protocol Number: CSPP100A2331 Start Date*: 2005-12-13
    Sponsor Name:Novartis Farmacéutuca, S.A.
    Full Title: An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / valsartan / HCTZ (300/320/25 mg), compared to the co...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005802-37 Sponsor Protocol Number: CSPP100A2256 Start Date*: 2009-05-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8 day open-label, multiple-dose, multi-center study to evaluate the safety/tolerability and pharmacokinetics of aliskiren in hypertensive pediatric and adolescent patients 6 – 17 years of age.
    Medical condition: hypertension
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-001176-12 Sponsor Protocol Number: CSPP100A2325 Start Date*: 2006-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study to compare the effects of multiple dose administration of aliskiren and irbesartan on biomarkers of inflammation and cardiovascular ri...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000250-55 Sponsor Protocol Number: RASQAL Start Date*: 2012-07-12
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für innere Medizin III
    Full Title: Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL)
    Medical condition: - Chronic kidney disease stages III-IV (defined by MDRD formula) - Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000286-19 Sponsor Protocol Number: CSPP100A2240 Start Date*: 2005-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patient...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000039-73 Sponsor Protocol Number: CSPP100A2327 Start Date*: 2005-07-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administer...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002621-23 Sponsor Protocol Number: SPV100A2301 Start Date*: 2006-09-28
    Sponsor Name:Novartis Pharma Services Ag
    Full Title: A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ valsartan 320 mg in patients with essential hypertension.
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001763-36 Sponsor Protocol Number: CSPP100A2347 Start Date*: 2006-12-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of Aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in st...
    Medical condition: Hypertension
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) CZ (Completed) BE (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 07:08:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA